Psychedelic Coming to the Workplace
summary
Companies describe deploying FDA‑approved ketamine via telehealth with 40,000 at-home treatments delivered and a tracked cohort of 640 treatment‑resistant patients showing 70% effectiveness to mild depression within a month; ketamine is said to act on glutamate, quiet the default mode network and temporarily reduce ego chatter, producing rapid effects compared with SSRIs. Parallel use of psilocybin is arranged legally as magic truffles in Amsterdam with mandatory preparation and integration services.
AI-written summary · about